Linlang Guo

Years Active: 2019-2023
Publications (10 Years): 6

Zhujiang Hospital

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Zhujiang Hospital

China

professor :: pathology

Publications

Ling Deng, Li Yang, Shuhan Zhu, Man Li, Yu Wang, Xiaolong Cao, Qiongyao Wang, Linlang Guo
Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening. Cell death discovery 9 (1) (2023)
Ling Deng, Li Yang, Shuhan Zhu, Man Li, Yu Wang, Xiaolong Cao, Qiongyao Wang, Linlang Guo
Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening. Cell death discovery 9 (1) (2023)
Ling Deng, Li Yang, Shuhan Zhu, Man Li, Yu Wang, Xiaolong Cao, Qiongyao Wang, Linlang Guo
Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening. Cell death discovery 9 (1) (2023)
Jian Zhou, Yang Wen, Xiangtian Chen, Linlang Guo
Bioinformatic Analysis of Prognostic Value of SNTG2 with Immune Implications in Lung Adenocarcinoma. International journal of general medicine 15 (2022)
Weimei Huang, Anqi Lin, Peng Luo, Yuchen Liu, Wentao Xu, Weiliang Zhu, Ting Wei, Qingwen Lyu, Linlang Guo, Jian Zhang
EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma. Cancer gene therapy 28 (7-8) (2020)
Jiarong Bao, Man Li, Shumei Liang, Yunchu Yang, Jingfang Wu, Qingqing Zou, Shun Fang, Size Chen, Linlang Guo
Integrated high-throughput analysis identifies super enhancers associated with chemoresistance in SCLC. BMC medical genomics 12 (1) (2019)

Linlang Guo.css-eqlu8i{font-size:small;padding-left:4px;}